Enlivex LtdENLV
Price$0.42

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Dec 2025
Net Income $1.2BTTM through 31 Dec 2025
Free Cash Flow -$10.5MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%

Returns

63.8%ROE
53.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio193.24x
Net Debt-$30Mnet cash position
Cash & Equivalents$1.9M

Quality Metrics

Altman Z-Score1.56
Piotroski F-Score4 / 9
Earnings-Beat Rate75.0%

Multi-Year Trend

Diluted EPS
'21'22'23'24'25
FY2025: $25.48

Dividend

No dividend

Capital Allocation

R&D Spend$9.2M

Segment Performance

SegmentRevenueYoYOutlook
Quality Longevity Therapeutics$0
View details

Advancing clinical trials and seeking regulatory pathways for Allocetra in osteoarthritis and other inflammatory indications.

Prediction Markets Treasury
View details

Exposure to decentralized forecasting markets infrastructure via the RAIN protocol.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.